Thiogenesis Announces Commencement of OTCQX Trading in the U.S.

Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company focused on developing disulfides that enhance the production of intracellular antioxidants and therapeutic compounds [1][5] - The company operates through its wholly owned subsidiary based in San Diego, California, and is listed on both the TSX Venture Exchange under the symbol TTI and the OTCQX Best Market under the symbol TTIPF [1][5] Market Activity - Thiogenesis' common shares are now trading on the OTCQX Best Market, which is the highest-level market of OTC Markets, enhancing visibility and accessibility to U.S. investors [1] - The company has achieved Depository Trust Company (DTC) eligibility status, allowing for electronic settlement of its common shares, which facilitates trading for U.S. investors [2] Clinical Development - On January 27, 2025, Thiogenesis announced it received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for the treatment of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS) [3] - The company is targeting serious pediatric diseases with unmet medical needs, including MELAS, Leigh's syndrome, Rett syndrome, and pediatric MASH [5] Disease Background - MELAS is a rare inherited mitochondrial disorder often caused by a mutation in the MT-TL1 gene, with initial symptoms including seizures, vomiting, and muscle weakness [4] - The disease typically presents before the age of 20 and has no approved drugs, making it a viable target for Thiogenesis' therapeutic development [4]